ProCE Banner Activity

PACIFIC: Improved OS With Durvalumab vs Placebo After CRT in Unresectable Stage III NSCLC

Slideset Download
Conference Coverage
Durvalumab significantly improved OS vs placebo in patients with locally advanced, unresectable, stage III NSCLC and no disease progression after previous concurrent CRT.

Released: September 28, 2018

Expiration: September 27, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology